Advances in Oral Delivery of Lipid Nanoparticles for Treating Inflammatory Diseases
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".
Deadline for manuscript submissions: 20 January 2025 | Viewed by 206
Special Issue Editors
2. State Key Laboratory of Silkworm Genome Biology, Key Laboratory for Sericulture Functional Genomics & Biotechnology of Agricultural Ministry, Southwest University, Beibei, Chongqing 400716, China
Interests: inflammatory bowel diseases; nanomedicines; drug delivery
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Oral delivery of lipid nanoparticles (LNPs) offers a promising approach for treating inflammatory diseases by enhancing the bioavailability and targeted delivery of therapeutic agents. LNPs can encapsulate anti-inflammatory drugs, protecting them from degradation in the gastrointestinal tract and facilitating their absorption through the intestinal lining. This method ensures controlled and sustained medication release, reducing the frequency of dosing and potentially minimizing side effects. Despite its potential, the design and preparation of orally deliverable LNPs face challenges, such as combating the complexity of inflammatory responses and requiring precise control over the size, surface charge, and composition of the particles. The development of new oral drug delivery systems may contribute to overcoming these difficulties.
This Special Issue aims to highlight the current progress in the use of orally delivered lipid nanoparticles as nanocarriers and nanotherapeutics in inflammatory diseases.
Dr. Dingpei Long
Dr. Junsik Sung
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- oral administration
- inflammatory diseases
- targeted drug delivery
- lipid nanoparticles
- engineered lipid nanoparticles
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
